Elsevier

Maturitas

Volume 46, Issue 3, 20 November 2003, Pages 213-218
Maturitas

The effects of hormone replacement therapy type on pulmonary functions in postmenopausal women

https://doi.org/10.1016/S0378-5122(03)00191-9Get rights and content

Abstract

Objective: To study whether hormone replacement therapy (HRT) or Tibolone has an effect on pulmonary function in postmenopausal women. Methods: Seventy-five postmenopausal women without any risk factor for pulmonary disease were included in this randomized, prospective study. Fifty women had undergone natural menopause and 25 had had a hysterectomy/ooforectomy. Twenty-five natural menopause women were randomly allocated to two groups: 25 patients (Group I) were treated with Tibolone 2.5 mg/day, 25 patients (group II) with Estradiol Hemihidrate 2 mg+Norethindron Asetate 1 mg/day. Twenty-five induced menopause women were treated with 17β-estradiol 2 mg/day. Lung function tests including forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1/FVC, forced expiratory flow rate over the 25–75% of the forced vital capacity volume (FEF25–75%), and peak expiratory flow rate (PEF) were evaluated at the beginning and 3 months after the treatment to assess the effects of HRT and Tibolone on respiratory function. Results: Regardless of HRT types a significant difference was observed in FVC and FEV1 after 3 months of the therapy (P=0.001, 0.0001, respectively). No significant difference was found between pre and post therapy values in the other parameters (P>0.05). Conclusions: We determined a significant increase in FVC and FEV1 parameters of pulmonary functions after 3 months of the therapy regardless of HRT types. Therefore, we think that HRT regimens have modifying effects on pulmonary function in postmenopausal women.

Introduction

Hypoestrogenism in menopause leads to a number of problems. Estradiol levels do not gradually decrease in the years before menopause, but remain in the normal range, and even slightly elevate [1]. Although new evidence about its benefits and harms requires reconsideration [2], [3], hormone replacement therapy (HRT) in the postmenopausal period is still in use because of its positive effects on treatment of menopausal symptoms, prevention of osteoporosis and colorectal cancer [3]. In studies on the effect of sex steroids on the respiratory system, there is evidence, which suggests that estrogen and progesterone may play a role in modifying pulmonary functions in young women [4], [5]. But, there is limited knowledge about the relationship between HRT and pulmonary functions in postmenopausal women. Menopause is generally associated with exacerbation of pre-existing asthma and, in addition, it may coincide with the clinical beginning of asthma [6]. One such study showed that estrogen therapy is associated with an inhibitory effect on the airway reactivity of bronchial smooth muscle [7]. In another study, which is a cross-sectional study, it was reported that postmenopausal women who used HRT had higher levels of forced expiratory volume (FEV1) and less airway obstruction, and that combined estrogen+progesterone users had higher pulmonary function levels than both nonusers and unopposed estrogen users [8]. However, we have encountered no study examining baseline spirometry values both before and after the initiation of HRT. Therefore, the purpose of this study was to determine the effects of HRT on pulmonary function in postmenopausal women and compare these effects for different HRT protocols.

Section snippets

Methods

Patients, who were admitted to the menopause clinic of our department for routine examinations and had never previously received HRT, were included in the study. All patients’ hormonal patterns were consistent with the menopausal period, i.e. increased plasma level of FSH and LH and decreased plasma levels of E2 [<20 pg/ml]. The patients’ current age, age at menopause, weight, height, and body mass index (BMI) were recorded. Patients with a cardiovascular system disease, metabolic disease,

Results

The patients’ current age, age at menopause, and BMI are shown in Table 1. There was no statistically significant difference between the groups regarding age, BMI and the duration of menopause (P>0.05). The groups’ pre- and post-therapy respiratory function parameters are shown in Table 2. While evaluating the pulmonary functions FVC, FEV1, FEV1/FVC, FEF25–75% and PEF, group x treatment period (pre- and post- treatment) interaction was not statistically significant, P values being 0.137, 0.164,

Discussion

In the present study, the effects of three different treatment protocols, namely estrogen, estrogen+progesterone, and tibolone, on respiratory function were compared. To the best of our knowledge, this is the first prospective, randomized study to examine the relationship between HRT use and pulmonary function in postmenopausal women.

The mean values of PFT parameters were in the normal range in this study. Regardless of HRT types, a significant increase was observed in FVC and FEV1 after 3

Conclusions

We determined a significant increase in FVC and FEV1 parameters of pulmonary functions after 3 months of treatment regardless of HRT type. These functional changes may imply that HRT regimens have modifying effects on pulmonary function in postmenopausal women.

References (19)

There are more references available in the full text version of this article.

Cited by (33)

  • Gender differences and sex-related hormonal factors in asthma

    2023, Asthma in the 21st Century: New Research Advances
  • Hormone replacement therapy and asthma onset in menopausal women: National cohort study

    2021, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    However, given that the Read codes for asthma diagnosis have been validated previously in a comparable database with high accuracy27 and the concomitance of asthma and chronic obstructive pulmonary disease based on Read codes is less than 15%,28 we believe such cases to be minimal if present and unlikely to change our conclusions. Although some previous studies have generally shown an increased risk of asthma onset with the use of HRT,15,18-23 contrary findings have also been reported.1-3,29-31 Most previous studies were cross-sectional.21-23

  • Exogenous female sex steroids may reduce lung ageing after menopause: A 20-year follow-up study of a general population sample (ECRHS)

    2019, Maturitas
    Citation Excerpt :

    Cevrioglu et al, in one of two clinical trials on volunteers, lasting three months, found an increased lung function in 23 women treated with a continuous estrogen and progestin preparation compared to 25 women who did not take HRT [17]. Pata et al, in the second trial on volunteers (N = 75) reported an increased lung function after treatment with Tibolone, combined estrogens and progestins as well as estrogen only preparations, but this study did not have a control group [18]. A drawback of both studies on volunteers might be that they are underpowered and subject to selection bias.

  • Estrogen replacement therapy and asthma

    2013, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    Therefore, the effects of estrogen were observed independently of progesterone or progestin, that are usually administered in combination with estrogen in women in which the uterus is conserved, in order to reduce the risk of endometrial estrogen-related hyperplasia or cancer. This finding is in accordance with those of several other studies, all of which demonstrated that HRT was associated with a significant increase in FEV1 [84–86] and in FVC [85,86] in postmenopausal women. Current knowledge concerning menopausal ERT and asthma provide evidence that estrogen have multiple actions that are, at least in part, conflicting.

  • Geoepidemiology of COPD and idiopathic pulmonary fibrosis

    2010, Journal of Autoimmunity
    Citation Excerpt :

    Consistent with this view are the results of a study of 1298 women who had irregular menstrual periods or were perimenopausal and had low forced vital capacity (FVC) and FEV1 [16,17]. In another group of postmenopausal women, three months of estrogen hormone replacement therapy increased FEV1 and FVC [18]. It is noteworthy that 75% of never-smokers with COPD are women over 55 years of age, lending further support to the concept that estrogen receptors may be mediating lung function [14].

View all citing articles on Scopus
View full text